Payment overview · 2025
General Payments
$267.33
14 reported records · 8 companies
Healthcare provider profile · identity verified
James A Briles, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PALMETTO, FL · NPI 1194722983
Verified facts
What the public records show
CMS Open Payments records show James A Briles, M.D. received $267.33 in general payments during 2025 across 14 reported records.
Exact Sciences Corporation accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $66.76 | 25.0% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $60.44 | 22.6% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $50.20 | 18.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.15 | 7.5% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.51 | 7.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.70 | 7.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.51 | 6.5% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.06 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $267.33 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $50.20 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $42.37 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $31.88 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.56 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.15 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.51 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $18.70 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.51 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $14.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 12 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
64 | 18 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 534 | 149 |
| Levothyroxine Sodium | Levothyroxine Sodium | 454 | 109 |
| Alprazolam | Alprazolam | 278 | 58 |
| Metformin Hcl | Metformin Hcl | 220 | 56 |
| Losartan Potassium | Losartan Potassium | 196 | 56 |
| Omeprazole | Omeprazole | 178 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 177 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 163 | 27 |
| Lisinopril | Lisinopril | 162 | 47 |
| Tramadol Hcl | Tramadol Hcl | 149 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 138 | 41 |
| Potassium Chloride | Potassium Chloride | 137 | 44 |
| Carvedilol | Carvedilol | 130 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 130 | 71 |
| Azithromycin | Azithromycin | 129 | 80 |
| Gabapentin | Gabapentin | 129 | 35 |
| Allopurinol | Allopurinol | 128 | 40 |
| Tamsulosin Hcl | Tamsulosin Hcl | 125 | 37 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 124 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 123 | 36 |
| Amlodipine Besylate | Amlodipine Besylate | 113 | 39 |
| Valsartan | Valsartan | 93 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 91 | 24 |
| Glimepiride | Glimepiride | 84 | 24 |
| Cefdinir | Cefdinir | 81 | 51 |
| Furosemide | Furosemide | 81 | 30 |
| Citalopram Hbr | Citalopram Hydrobromide | 78 | 19 |
| Metoprolol Succinate | Metoprolol Succinate | 72 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 69 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 66 | 12 |
| Dexamethasone | Dexamethasone | 65 | 50 |
| Meloxicam | Meloxicam | 65 | 21 |
| Eliquis | Apixaban | 64 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 63 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 15 |
| Temazepam | Temazepam | 58 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 55 | 42 |
| Simvastatin | Simvastatin | 55 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 54 | 12 |
| Trazodone Hcl | Trazodone Hcl | 53 | 15 |
| Finasteride | Finasteride | 51 | 18 |
| Famotidine | Famotidine | 48 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 13 |
| Clonidine Hcl | Clonidine Hcl | 45 | 16 |
| Diazepam | Diazepam | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | suppressed |
| Lorazepam | Lorazepam | 36 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 35 | suppressed |
| Pregabalin | Pregabalin | 35 | suppressed |
| Spironolactone | Spironolactone | 35 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Nifedipine Er | Nifedipine | 33 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 12 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 15 |
| Celecoxib | Celecoxib | 29 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 28 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 26 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 25 | 12 |
| Ssd | Silver Sulfadiazine | 25 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 23 | 13 |
| Ozempic | Semaglutide | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 22 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 21 | 14 |
| Sertraline Hcl | Sertraline Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 20 | 12 |
| Estradiol | Estradiol | 20 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Eszopiclone | Eszopiclone | 17 | suppressed |
| Methylprednisolone | Methylprednisolone | 17 | 15 |
| Norethindron-Ethinyl Estradiol | Norethindrone Ac/Eth Estradiol | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Xarelto | Rivaroxaban | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 15 | suppressed |
| Clonazepam | Clonazepam | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 14 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mirtazapine | Mirtazapine | 13 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 12 |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $267.33 · 14 records | Exact Sciences Corporation | AIRSUPRA, BREZTRI, Cologuard Collection Kit, EVENITY, Ozempic, PAXLOVID, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VENASEAL, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error